Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis

Frontiers in Immunology

Volumn 7, Issue JUN, 2016, Pages

  Subbian, Selvakumar ^a   Koo, Mi Sun ^a,b   Tsenova, Liana ^a,c   Khetani, Vikram ^d   Zeldis, Jerome B ^d   Fallows, Dorothy ^a   Kaplan, Gilla ^e  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NYC College of Technology   (United States)

^d CELGENE CORPORATION   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Gene expression; Host directed therapy; Immune modulation; Mouse model; Mycobacterium tuberculosis; Phosphodiesterase 4 inhibitor; Pulmonary tuberculosis

Indexed keywords

CYTOCHROME P450; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IFI35 PROTEIN; IFIT3 PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 17; IRG1 PROTEIN; ISONIAZID; LYMPHOCYTE ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 4; N [2 [ 1 (3 ETHOXY 4 METHOXYPHENYL) 2 (METHYLSULFONYL) ETHYL] 2,3 DIHYDRO 3 OXO 1H ISOINDOL 4 YL] (9CL) CYCLOPROPANECARBOXAMIDE); PEPTIDES AND PROTEINS; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; STAT1 PROTEIN; STAT2 PROTEIN; TRIADIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE ONTOLOGY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84977515312     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00238     Document Type: Article

References (29)

1. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet (2015) 385(9979):1799-801. doi: 10.1016/S0140-6736(15)60570-0
2. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest (2007) 131(6):1817-24. doi:10.1378/chest.06-2949
3. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, BorgdorffMW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med (2005) 171(12):1430-5. doi:10.1164/rccm.200409-1200OC
4. Ross J, Ehrlich RI, Hnizdo E, White N, Churchyard GJ. Excess lung function decline in gold miners following pulmonary tuberculosis. Thorax (2010) 65(11):1010-5. doi:10.1136/thx.2009.129999
5. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 4(3):e120. doi:10.1371/journal.pmed.0040120
6. Ruan Q, Liu Q, Sun F, Shao L, Jin J, Yu S, et al. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microbes Infect (2016) 5(1):e12. doi:10.1038/emi.2016.12
7. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol (2015) 15(4):255-63. doi:10.1038/nri3813
8. Zumla A, Azhar EI, Arabi Y, Alotaibi B, Rao M, McCloskey B, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis (2015) 40:71-4. doi:10.1016/j.ijid.2015.09.005
9. Aldridge BB, Keren I, Fortune SM. The spectrum of drug susceptibility in Mycobacteria. Microbiol Spectr (2014) 2(5):MGM2-0031-2013. doi:10.1128/microbiolspec. MGM2-0031-2013
10. Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol (2010) 64:293-311. doi:10.1146/annurev.micro.112408.134043
11. Koo MS, Manca C, Yang G, O'Brien P, Sung N, Tsenova L, et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One (2011) 6(2):e17091. doi:10.1371/journal.pone.0017091
12. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 7(9):e1002262. doi:10.1371/journal.ppat.1002262
13. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol (2011) 179(1):289-301. doi:10.1016/j.ajpath.2011.03.039
14. Subbian S, Tsenova L, Holloway J, Peixoto B, O'Brien P, Dartois V, et al. Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model. EBioMedicine (2016) 4:104-14. doi:10.1016/j.ebiom.2016.01.015
15. Koo MS, Subbian S, Kaplan G. Strain specific transcriptional response in Mycobacterium tuberculosis infected macrophages. Cell Commun Signal (2012) 10(1):2. doi:10.1186/1478-811X-10-2
16. Lyadova IV, Panteleev AV. Th1 and Th17 Cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm (2015) 2015:854507. doi:10.1155/2015/854507
17. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence (2010) 1(5):423-7. doi:10.4161/viru.1.5.12862.Review
18. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med (2009) 30(4):769-82, ix. doi:10.1016/j.ccm.2009.08.009
19. Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis (2013) 208(3):512-9. doi:10.1093/infdis/jit187
20. Maiga MC, Ahidjo BA, Maiga M, Bishai WR. Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis. Antimicrob Agents Chemother (2015) 59(12):7888-90. doi:10.1128/AAC.02145-15
21. Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse (2002) 45(4):259-69. doi:10.1002/syn.10100
22. Konrad FM, Bury A, Schick MA, Ngamsri KC, Reutershan J. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. PLoS One (2015) 10(4):e0121725. doi:10.1371/journal.pone.0121725
23. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J (2003) 370(Pt 1):1-18.
24. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol (2002) 57(11):799-804. doi:10.1007/s00228-001-0396-3
25. Flynn J, Tsenova L, Izzo A, Kaplan G. Experimental animal models of tuberculosis. In: Kaufmann SHE, Britton WJ, editors. Handbook of Tuberculosis-Immunology and Cell Biology. Weinheim: Wiley-VCH Verlag GmBH & Co. KGaA (2008). p. 389-426.
26. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med (1966) 123(3):445-68. doi:10.1084/jem.123.3.445
27. Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, et al. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med (2016) 213(5):809-25. doi:10.1084/jem.20151248
28. Tsenova L, O'Brien P, Holloway J, Peixoto B, Soteropoulos P, Fallows D, et al. Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. J Interferon Cytokine Res (2014) 34(9):716-26. doi:10.1089/jir.2013.0123
29. Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A (2015) 112(6):1827-32. doi:10.1073/pnas.1424563112